Can EBP50 and Merlin be used as diagnostic and prognostic markers for uterine smooth muscle tumors?

References

• Horn LC, Hiller GGR, Mayr D, et al. Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification. Pathologe. 2022;43(3):196–201. doi: 10.1007/s00292-022-01064-6.
   PubMed Web of Science ®Google Scholar
• Tsukada H, Muramatsu T, Miyazawa M, et al. Long term prognostic implications of expression of glucose transporter- 1 and hexokinase II in patients with stage I uterine leiomyosarcoma. Acta Histochem Cytochem. 2012;45(2):147–154. doi: 10.1267/ahc.11063.
   PubMed Web of Science ®Google Scholar
• Gökaslan H, Türkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59(1):36–40. doi: 10.1159/000080933.
   PubMed Web of Science ®Google Scholar
• Poncelet C, Walker F, Madelenat P, et al. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol. 2001;32(11):1190–1196. doi: 10.1053/hupa.2001.28935.
   PubMed Web of Science ®Google Scholar
• Ünver NU, Acikalin MF, Öner Ü, et al. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet. 2011;284(2):483–490. doi: 10.1007/s00404-010-1690-z.
   PubMed Web of Science ®Google Scholar
• Alabalık U, Türkcü G, Keleş AN, et al. Can aquaporins be used as diagnostic and prognostic markers for uterine smooth muscle tumours? 2017; Biotechnology & Biotechnological Equipment. 2017;31(1):148–155. doi: 10.1080/13102818.2016.1240018.
   Web of Science ®Google Scholar
• Weinman EJ, Steplock D, Wang Y, et al. Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane na(+)-H + exchanger. J Clin Invest. 1995;95(5):2143–2149. doi: 10.1172/JCI117903.
   PubMed Web of Science ®Google Scholar
• Lema BE, Patricio GM, Kreimann EL. Nuclear expression of NHERF1/EBP50 in clear cell renal cell carcinoma. Acta Histochem. 2021;123(5):151717. doi: 10.1016/j.acthis.2021.151717.
   PubMed Web of Science ®Google Scholar
• Centonze M, Saponaro C, Mangia A. NHERF1 Between promises and hopes: overview on cancer and prospective openings. Transl Oncol. 2018;11(2):374–390. doi: 10.1016/j.tranon.2018.01.006.
   PubMed Web of Science ®Google Scholar
• Vaquero J, Nguyen Ho-Bouldoires TH, Clapéron A, et al. Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance. Oncogene. 2017;36(22):3067–3079. doi: 10.1038/onc.2016.462.
   PubMed Web of Science ®Google Scholar
• Nguyen R, Reczek D, Bretscher A. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem. 2001;276(10):7621–7629. doi: 10.1074/jbc.M006708200.
   PubMed Web of Science ®Google Scholar
• Georgescu MM, Mobley BC, Orr BA, et al. NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathol Commun. 2016;4(1):55. doi: 10.1186/s40478-016-0329-0.
   PubMedGoogle Scholar
• Curto M, Cole BK, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893–903. doi: 10.1083/jcb.200703010.
   PubMed Web of Science ®Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104(3):177–178. doi: 10.1016/j.ijgo.2008.12.008.
   PubMedGoogle Scholar
• Matias-Guiu X, Oliva E, McCluggage WG, et al. WHO classification of tumours of female genital tumours: tumours of the uterine corpus. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020.
   Google Scholar
• Fuchs I, Vorsteher N, Bühler H, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res. 2007;27:959–963.
   PubMed Web of Science ®Google Scholar
• Kaur K, Kaur P, Kaur A, et al. Uterine leiomyosarcoma: a case report. J Midlife Health. 2014;5(4):202–204. doi: 10.4103/0976-7800.145175.
   PubMedGoogle Scholar
• Sait HK, Anfinan NM, El Sayed ME, et al. Uterine sarcoma. Clinico-pathological characteristics and outcome. Saudi Med J. 2014;35:1215–1222.
   PubMed Web of Science ®Google Scholar
• Sonnessa M, Sergio S, Saponaro C, et al. The biological relevance of NHERF1 protein in gynecological tumors. Front Oncol. 2022;12:836630. doi: 10.3389/fonc.2022.836630.
   PubMed Web of Science ®Google Scholar
• Oh YS, Heo K, Kim EK, et al. Dynamic relocalization of NHERF1 mediates chemotactic migration of ovarian cancer cells toward lysophosphatidic acid stimulation. Exp Mol Med. 2017;49(7):e351. doi: 10.1038/emm.2017.88.
   PubMedGoogle Scholar
• Tao T, Yang X, Qin Q, et al. NHERF1 enhance cisplatin sensitivity in human cervical cancer cells. Int J Mol Sci. 2017;18(1):5. doi: 10.3390/ijms18010005.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Yoki A, Konno R, et al. Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma. Carcinogenesis. 2021;42(9):1162–1170. doi: 10.1093/carcin/bgab070.
   PubMed Web of Science ®Google Scholar
• Wang L, Qi Y, Xiong Y, et al. Ezrin-Radixin-moesin binding phosphoprotein 50 (EBP50) suppresses the metastasis of breast cancer and HeLa cells by ınhibiting ­matrix metalloproteinase-2 activity. Anticancer Res. 2017;37(8):4353–4360. doi: 10.21873/anticanres.11829.
   PubMed Web of Science ®Google Scholar
• Hoque MT, Cole SP. Down-regulation of na+/H + exchanger regulatory factor 1 ıncreases expression and function of multidrug resistance protein 4. Cancer Res. 2008;68(12):4802–4809. doi: 10.1158/0008-5472.CAN-07-6778.
   PubMed Web of Science ®Google Scholar
• Georgescu MM, Morales FC, Molina JR, et al. Roles of NHERF1/EBP50 in cancer. Curr. Mol. Med. 2008;8:459–468. doi: 10.2174/156652408785748031.
   PubMed Web of Science ®Google Scholar
• Shibata T, Chuma M, Kokubu A, et al. EBP50, a beta-catenin-associating protein, enhances WNT signaling and is over-expressed in hepatocellular carcinoma. Hepatology. 2003;38(1):178–186. doi: 10.1053/jhep.2003.50270.
   PubMed Web of Science ®Google Scholar
• Lin YY, Hsu YH, Huang HY, et al. Aberrant nuclear localization of EBP50 promotes colorectal carcinogenesis in xenotransplanted mice by modulating TCF-1 and β-catenin interactions. J Clin Invest. 2012;122(5):1881–1894. doi: 10.1172/JCI45661.
   PubMed Web of Science ®Google Scholar
• Mangia A, Saponaro C, Malfettone A, et al. Involvement of nuclear NHERF1 in colorectal cancer progression. Oncol Rep. 2012;28(3):889–894. doi: https://doi.org/10.3892/or.2012.1895.
   PubMed Web of Science ®Google Scholar
• Paradiso A, Scarpi E, Malfettone A, et al. Nuclear NHERF1 expression as a prognostic marker in breast cancer. Cell Death Dis. 2013;4(11):e904. doi: 10.1038/cddis.2013.439.
   PubMedGoogle Scholar
• Mota M, Shevde LA. Merlin regulates signaling events at the nexus of development and cancer. Cell Commun Signal. 2020;18(1):63. doi: 10.1186/s12964-020-00544-7.
   PubMed Web of Science ®Google Scholar
• Petrilli AM, Fernández-Valle C. Role of merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537–548. doi: 10.1038/onc.2015.125.
   PubMed Web of Science ®Google Scholar
• Sato T, Sekido Y. NF2/Merlin ınactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4):988. doi: 10.3390/ijms19040988.
   PubMed Web of Science ®Google Scholar
• Sekido Y, Sato T. NF2 alteration in mesothelioma. Front Toxicol. 2023;5:1161995. doi: 10.3389/ftox.2023.1161995.
   PubMedGoogle Scholar
• Quan M, Cui J, Xia T, et al. Merlin/NF2 suppresses pancreatic tumor growth and metastasis by attenuating the FOXM1-mediated wnt/β-Catenin signaling. Cancer Res. 2015;75(22):4778–4789. doi: 10.1158/0008-5472.CAN-14-1952.
   PubMed Web of Science ®Google Scholar